Ajanta Pharma's Q1 FY 2026-27 Quarterly Results

Result Summary

• Ajanta Pharma Ltd reported a 14.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 27.7%.
• Its expenses for the quarter were up by 10.0% QoQ and 25.3% YoY.
• The net profit increased 25.3% QoQ and increased 30.9% YoY.
• The earnings per share (EPS) of Ajanta Pharma Ltd stood at 26.72 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ajanta Pharma Ltd is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company specializes in the production of generic pharmaceuticals and is known for its presence in the therapeutic areas of cardiovascular, dermatology, ophthalmology, and pain management, among others. Ajanta Pharma operates in both domestic and international markets, with a significant focus on emerging markets. Recent major developments concerning Ajanta Pharma are not specified in the available data, but the company has been known for its strategic expansions and focus on innovation.

Revenue

During Q1FY27, Ajanta Pharma Ltd reported a total income of ₹1696.86 crores, illustrating a quarter-over-quarter (QoQ) increase of 14.4% from ₹1483.07 crores in Q4FY26. On a year-over-year (YoY) basis, the total income rose by 27.7% compared to ₹1328.98 crores in Q1FY26. These figures indicate growth in the company's revenue streams over both the quarter and year. The financial data suggests improved market performance or product sales contributing to higher income levels.

Profitability

Ajanta Pharma Ltd's Profit Before Tax (PBT) for Q1FY27 amounted to ₹446.80 crores, reflecting a 28.7% increase from Q4FY26's ₹347.11 crores. Year-over-year, PBT grew by 34.9% from ₹331.13 crores in Q1FY26. The tax expense for the quarter was ₹112.58 crores, up 40.0% from the previous quarter and 48.5% year-over-year. Consequently, the Profit After Tax (PAT) for Q1FY27 was ₹334.22 crores, increasing by 25.3% QoQ and 30.9% YoY. This progression in profitability metrics suggests enhanced cost management or revenue efficiency, leading to improved net earnings.

Operating Metrics

The total expenses for Ajanta Pharma in Q1FY27 were ₹1250.06 crores, which is a 10.0% increase from ₹1135.96 crores in Q4FY26 and a 25.3% rise from ₹997.85 crores in Q1FY26. The Earnings Per Share (EPS) for the quarter stood at ₹26.72, representing a 25.2% increase from ₹21.34 in the previous quarter and a 30.8% rise from ₹20.43 in the same quarter last year. These figures indicate a substantial increase in operational costs, but the company still managed to maintain an upward trend in earnings per share, reflecting efficient operational management and profitability for shareholders.